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CPI-17 (C-kinase-activated protein phosphatase-1 (PP1) inhibitor, 17kDa) is a cytoplasmic protein 
predominantly expressed in mature smooth muscle (SM) that regulates the myosin-associated PP1 
holoenzyme (MLCP). Here, we show CPI-17 expression in proliferating cells, such as pancreatic cancer 
and hyperplastic SM cells. Immunofluorescence showed that CPI-17 was concentrated in nuclei of 
human pancreatic cancer (Panc1) cells. Nuclear accumulation of CPI-17 was also detected in the 
proliferating vascular SM cell culture and cells at neointima of rat vascular injury model. The N-terminal 
21-residue tail domain of CPI-17 was necessary for the nuclear localization. Phospho-mimetic Asp-
substitution of CPI-17 at Ser12 attenuated the nuclear import. CPI-17 phosphorylated at Ser12 was not 
localized at nuclei, suggesting a suppressive role of Ser12 phosphorylation in the nuclear import. 
Activated CPI-17 bound to all three isoforms of PP1 catalytic subunit in Panc1 nuclear extracts. CPI-17 
knockdown in Panc1 resulted in dephosphorylation of histone H3 at Thr3, Ser10 and Thr11, whereas it 
had no effects on the phosphorylation of myosin light chain and merlin, the known targets of MLCP. In 
parallel, CPI-17 knockdown suppressed Panc1 proliferation. We propose that CPI-17 accumulated in 
the nucleus through the N-terminal tail targets multiple PP1 signaling pathways regulating cell 
proliferation.  
 
  
 
Abbreviations:  PP1, protein phosphatse-1; CPI-17, PKC-activated PP1 inhibitor (Mr=17kDa); MLCP, 
myosin light chain phosphatase; MYPT1, myosin phosphatase targeting subunit, GFP, green 
fluorescence protein; PKC, protein kinase C; ROCK, RhoA-associated coiled coil kinase. 
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INTRODUCTION 
  
Abnormal acceleration in epithelial and mesenchymal cell proliferation is a hallmark of 
tumorigenesis and hyperplasia. Protein phosphatase-1 (PP1) is a dominant Ser/Thr phosphatase in 
eukaryotic cells, and known to play multiple roles in the regulation of cell proliferation. The catalytic 
subunits of PP1 (PP1C), consisting of four isoforms (,   1, and testis-specific 2), are capable 
of dephosphorylating a range of cellular proteins.  Each PP1C isoform is assembled with a specific 
group of polypeptides, known as targeting subunits or interacting proteins, which regulate specific 
activity and compartmentalize PP1 at subcellular loci [1,2].  In addition to over 200 PP1 targeting 
subunits, 10 polypeptides specifically inhibit cellular PP1 holoenzymes in mammalian cells, classified 
into PP1 inhibitor proteins [1,2,3]. Characterization of PP1 targeting subunits and the endogenous 
inhibitors that mediate signals regulating cell proliferation is vital to fully understand mechanisms 
causing hyperplasia,  
CPI-17 was discovered as a specific inhibitor for the myosin light chain phosphatase (MLCP), 
consisting of the PP1C () isoform associated with MYPT1, the myosin-targeting subunit.  CPI-17 is 
highly expressed (at µM levels) in mature smooth muscles (SM) [4]. In mature SM, G-protein-coupled 
receptor signals trigger the activation of PKC and ROCK that phosphorylate CPI-17 at Thr38.  This 
phosphorylation enhances the inhibitory potency of CPI-17 over 1,000-fold, resulting in MLCP inhibition, 
and consequent elevation in myosin light chain phosphorylation, causing SM contraction.  The CPI-17-
mediated MLCP regulation plays pivotal roles in adjusting responsiveness of SM contraction to stimuli, 
a process known as Ca2+ sensitization [3,5,6].  Accumulating lines of evidence suggest that changes in 
CPI-17 levels are associated with impaired excitation-contraction coupling of SM under pathological 
conditions, such as hypertension, asthma, gastrointestinal diseases, and urinary tract dysfunctions 
(reviewed in [3,7]).  
The CPI-17 protein consists of a central four-helix bundle domain sandwiched with intrinsically 
unstructured N- and C-terminal tails. The central domain, whose structure is conserved among 
members of the CPI-17 family, such as PHI-1, KEPI and GBPI, is necessary and sufficient for the 
phosphorylation-dependent inhibition of MLCP [7].  Purified phospho (P)-CPI-17 inhibits MLCP with 
IC50 of <10nM and the isolated PP1C with lesser potency (reviewed in [3,7]). The inhibitory 
phosphorylation site, Thr38, resides in the loop region adjacent to the four-helix bundle. P-Thr38 in the 
loop directly docks at the bi-metal active site of PP1C, causing competitive inhibition [8]. In the MLCP 
holoenzyme, MYPT1 contacts both PP1C and CPI-17, stabilizing the enzyme-inhibitor interaction [7,9]. 
On the other hand, PP1C assembled with other PP1 targeting subunits, such as the glycogen-targeting 
subunit, rapidly dephosphorylates P-CPI-17 as a substrate and thereby neutralizes the inhibitory action 
[8]. Thus, PP1 targeting subunits determine whether CPI-17 acts as a specific inhibitor or a substrate of 
PP1C. What has yet to be fully evaluated is whether P-CPI-17 regulates only MLCP among >200 PP1 
holoenzymes in cells.  
Upon de-differentiation of SM cells, CPI-17 expression declines to 10% of the level in mature 
SM [10,11,12].  It is worth noting that the expression level of CPI-17 in de-differentiated SM cells 
remains over 10-fold greater compared to the IC50 with MLCP. Recently, CPI-17 was suggested to 
inhibit MLCP in SM cell culture and regulate MEF2C-mediated SM differentiation [13]. Also, it has been 
claimed that MLCP is a target of CPI-17 in cancer cells [14].  On the other hand, ectopic CPI-17 protein 
expressed in fibroblasts and in SM cell culture accumulates in nuclei [13,15], leaving open the 
possibility of CPI-17 regulating PP1 signaling in the nucleus. Here, we determined that CPI-17 is 
actively imported into nuclei and regulates histone phosphorylation and cell proliferation. 
 
 
MATERIALS AND METHODS 
Immunofluorescence and immunohistochemistry:  Immunofluorescence and immunohistochemistry 
were performed as described previously [11,15].  Briefly, cells seeded on fibronectin-coated coverslip 
were fixed with 4% paraformaldehyde, and permeabilized with 0.1% Triton X-100, followed by indirect 
immunostaining.  Paraffin-embedded sections of rat aorta at 14 weeks after balloon-catheter injury (gift 
from Dr. Avril V. Somlyo at University of Virginia) were prepared and processed as described previously 
[11]. Samples stained without primary antibodies were used as blank (BLK).  Fluorescence microscopy 
and spot densitometry of digital images were done using the spinning-disk confocal microscope 
(Olympus IX70 plus BD CARV-II) with BD IPLab imaging software [11]. Nuclear / cytoplasmic (N/C) 
Index was defined as the ratio of staining densities at the nucleus and the cytoplasm of a cell.  Mean 
values ± SEM of N/C index were obtained from 8-10 cells.  
 
Others:  Total protein extracts of human pancreatic cancer cell lines (L3.6pl, AsPC-1 and BxPC-3) and 
the 3xGFP tag expression vector were gifts from Drs J. Thomas Persons and Ian Macara at University 
of Virginia, respectively.  QRTPCR and immunoblotting were done as described previously [12].  Cell 
proliferation was assayed in triplicate using Panc1 cells treated with negative control or CPI-17 
targeting siRNA.  Cells were treated with siRNA for 72 h in the presence of 10% FBS, fixed with dry 
methanol, stained with hematoxylin solution (Sigma), and counted under microscope.  Mean values ± 
SEM of the number of cells were obtained from at least three image fields in each dish. Asterisk in each 
figure indicates p<0.05 in Student t-test compared to control. Conditions of cell culture, siRNA 
knockdown, transient transfection [12], subcellular fractionation [16] and pulldown assay [8] are 
described in Supplemental information.  All primary and secondary antibodies used were listed in 
Supplemental table 1.  
 
 
RESULTS 
Expression and nuclear localization of CPI-17 in cancer and SM cells:  We determined the levels of 
CPI-17 mRNA and protein using quantitative RTPCR and immunoblotting (Fig. 1A and B). In QRTPCR 
analysis (Fig. 1A), CPI-17 mRNA was especially abundant in pancreatic cancer cells (Panc1), 
compared with fibroblasts (HEK293) and other cancer cell lines, such as cervical adenocarcinoma 
(HeLa), neuroblastoma (SH-SY5Y), and leiomyosarcoma (SK-LMS1). To estimate CPI-17 protein levels, 
extracts of rat aorta tissue and cancer cells (10µg each) were subjected to immunoblotting with anti-
CPI-17 (Fig. 1B).  Actin was stained for loading control. CPI-17 protein was detected in Panc1 cells at 
approximately 10% of the level in aorta tissue, but not in the SM-derived LMS1 cells (Fig. 1B, left).  The 
level in Panc1 cells is equivalent to that of the SM cell culture [10,11]. Among human pancreatic cancer 
cell lines (Fig. 1B, right), CPI-17 expression was prominent in Panc1 cells and at lower levels in AsPC-1 
and BxPC3 pancreatic cancer cell lines. CPI-17 was also expressed in different derivatives of Panc-1 
cells (data not shown).  Thus, Panc1 can be a model for studying roles of CPI-17 in proliferating cells.   
We examined the subcellular localization of CPI-17 by immunofluorescent microscopy of Panc1 
and rat aorta SM cell culture (Fig. 1C), and rat aorta wall cross sections (Fig. 1D). Prominent staining 
for CPI-17 was co-localized with Hoechst staining in Panc1 (Fig. 1C top left), whereas no nuclear 
staining was detected without the primary antibody as a control for specificity (Fig. 1C, top right). 
Release of platelet-derived growth factor and basic fibroblast growth factor converts 
contractile/quiescent SM cell at vascular media into the proliferative phenotype, which is mimicked by 
the SM cells explanted from tissues. As shown in Fig. 1C (bottom panels), nuclear localization of CPI-
17 was detected in rat aortic SM cell culture, a well-characterized model of the hyperplastic SM. We 
further examined subcellular localization of CPI-17 using an established in vivo model of hyperplastic 
SM cells. Physical damage of endothelium of rat aorta triggers proliferation and migration of SM cells, 
leading to neointima formation, a model of atherosclerosis and restenosis.  We have shown that CPI-17 
is downregulated in neointima, compared with the cells at SM layers [11].  Fig. 1D show 
immunohistochemistry of paraffin-embedded artery section at 14 week after injury co-stained with anti-
CPI-17, anti-smooth muscle type (sm)-actin and Hoechst.  CPI-17 was detected throughout cells at SM 
layers in tunica media.  On the other hand, CPI-17 in the cells at neointima was concentrated in nuclei 
(Fig. 1D, arrows), which is evident in the merged image of CPI-17 staining with Hoechst staining (right 
panel).  These cells at neointima also expressed sm-actin that was excluded from nuclei (Fig. 1D).  
These results suggest that CPI-17 nuclear localization occurs when it is expressed in cells with the 
proliferative phenotype.  
 
Mechanisms underlying CPI-17 nuclear localization:  The molecular basis of CPI-17 nuclear localization 
was investigated using COS1 cells transiently expressing triple-GFP (3xGFP) tagged protein (Fig. 2A-
L). To mimic the modest level of the endogenous protein, expression of 3xGFP protein was limited to 
minimum, and visualized by immunofluorescence using anti-GFP antibody. Intrinsic GFP fluorescence 
images of live and fixed cells under epifluorescence are shown in Supplemental figure 1.  In the 
confocal images, ectopic 3xGFP protein alone (“empty”) was excluded from nuclei due to the size 
(Mr=78kDa) (Fig. 2, panel B, G).  We quantified staining intensities of the proteins in regions of the 
nucleus and the cytoplasm by spot densitometry.  The ratio of nuclear staining to cytoplasmic staining 
(“N/C Index”) was below 0.5 (panel L), indicating the exclusion of 3xGFP protein from the nucleus (Fig. 
2L, “Empty”).  By sharp contrast, 3xGFP protein fused with CPI-17 wild type (WT) was accumulated in 
nuclei (panel C, H) with N/C Index of over 1.5 (panel L). As shown in Fig. 2A, the N-terminal tail of CPI-
17 forms a basic-residue cluster, similar to nuclear import signal [17]. Indeed, the deletion of the N-
terminal 21-residue eliminated the nuclear accumulation of CPI-17 (Fig. 2D, I, L: 3xGFP-CPI-17(∆N)), 
suggesting a functional nuclear localization signal (NLS) in the unstructured N-terminal tail. Purified 
kinases, such as PKC, ZIPK, ROCK and ILK, can phosphorylate CPI-17 at Ser12 in the middle of the 
N-terminal NLS region (Fig. 2A, marked by dot) [7].  Asp-substitution mimicking the phosphorylation at 
Ser12 (3xGFP-CPI-17(S12D)) diminished the nuclear localization (Fig. 2F, K, L), whereas Ala-
substitution at Ser12 had no effect (Fig. 2E, J, L).  
To determine roles of Ser12 phosphorylation in the nuclear localization, we developed the 
antibody recognizing P-Ser12, but not P-Thr38 (Supplemental figure 2). To confirm Ser12 
phosphorylation in cells, HEK293 cells expressing HA-tagged CPI-17 was stimulated with phorbol ester 
(PMA) and subjected to immunoblotting (Fig. 2M).  CPI-17 phosphorylated at Ser12 was detected in the 
cell lysates of the quiescent cells, and cells stimulated with PMA at slightly higher level (Fig.2M).  Thr38 
phosphorylation was enhanced in response to PMA stimulation, as we reported previously [10]. Rat 
fundus SM cells expressing higher level of endogenous CPI-17 were fixed with 10% TCA and subjected 
to co-immunostaining with the anti-P-S12-CPI-17 antibody plus anti-total CPI-17 and Hoechst (Fig. 2N-
T). Unlike total CPI-17 staining (panel N), P-Ser12-CPI-17 staining (panel O) did not show any nuclear 
accumulation with N/C index of around 1.0 (panel T), indicating free diffusion in the cells. On the other 
hand, cells stained without primary antibodies (panel Q, R, S) did not show any background signal 
under the condition.  These results suggest that the phosphorylation of CPI-17 at the N-terminal tail is 
sufficient to attenuate the NLS activity. 
 
CPI-17 regulates phosphorylation of nuclear proteins and cell proliferation: We questioned what was 
the target of nuclear CPI-17. As shown in Fig. 3A, the sequential extraction of Panc1 cells showed that 
majority of MYPT1 existed in the soluble fraction, which is consistent with the report by Murata et al [18].  
A small amount of MYPT1 was extracted from nuclei along with Sp1 protein a marker of nuclear 
proteins (Fig. 3A). This is consistent with the data in proteomics that showed MYPT1 in nuclear extracts, 
in addition to approximately 20 other PP1-binding polypeptides [19,20]. The soluble fraction and 
nuclear extracts were subjected to a CPI-17 pulldown assay (Fig. 3A, B). Both MYPT1 and PP1C in the 
soluble fraction bound to tP-CPI-17-beads, but not to unphosphorylated (U)-CPI-17 or blank beads 
(BLK), demonstrating the phosphorylation-dependent binding of CPI-17 to the MYPT1-PP1C complex 
(Fig. 3A). MYPT1 in the nuclear extracts failed to bind tP-CPI-17 beads (Fig. 3A), although tP-CPI-17 
bound to all isoforms of PP1C, (, , and 1) in nuclear extracts (Fig. 3B). Because most nuclear PP1 
targeting subunits recognize specific PP1C isoforms, CPI-17 likely binds multiple types of nuclear PP1 
holoenzymes in nuclei.   
We determined phosphorylation of established substrate proteins for MLCP in Panc1 cells after 
CPI-17 knockdown (Fig. 4). siRNA knockdown effectively eliminated CPI-17 protein without changing 
the expression of PP1C isoforms (Fig. 4A, left).  Remarkably, the phosphorylation of myosin light chain 
(LC20), merlin (MLN) and ezrin/radixin/moesin (ERM), the major substrates of MLCP, did not change in 
response to CPI-17 knockdown (Fig. 4A, right).  On the other hand, CPI-17 knockdown resulted in the 
net de-phosphorylation of histone H3 at Thr3 (P-H3T3), at Ser10 (P-H3S10) and at Thr11 (P-H3T11) 
(Fig. 4A, right). As shown in Fig. 4B, after a 72-h treatment with control siRNA, the number of Panc1 
cells increased 2.5-fold, whereas CPI-17 knockdown resulted in a 40 % reduction in Panc1 proliferation. 
These results suggest that CPI-17 in the nucleus inhibits a subset of PP1 responsible for 
dephosphorylation of histone H3, upregulating cell proliferation signaling.   
 
 
DISCUSSION 
In this report we present evidence suggesting that CPI-17 regulates nuclear PP1 signaling 
pathways.  Based on the model established in mature SM tissues [3,7,21], CPI-17 was anticipated to 
inhibit MLCP in cancer cells, amplifying Ras signaling through merlin phosphorylation [14], and in 
vascular SM cell culture, regulating MEF2C and the differentiation [13].  By sharp contrast, our finding 
shows that CPI-17 inhibits nuclear PP1 responsible for histone H3 dephosphorylation. The suppression 
of Panc1 proliferation by CPI-17 knockdown may be attributed to the histone H3 dephosphorylation, 
because the temporal phosphorylation is required for chromatin remodeling during the cell cycle. 
MYPT1 possesses an active NLS at the N-terminal domain and is detected in nuclear extracts [20,22].  
Clearly, MYPT1 in nuclei is not accessible for CPI-17.  We presume that MYPT1 in the nucleus is not in 
complex with PP1C [23], otherwise it would have bound to tP-CPI-17. Or, unknown posttranslational 
modifications of MYPT1 interfere CPI-17 binding. Over 20 polypeptides in nuclei are found to bind 
PP1C, and each of them is a potential target of P-CPI-17 [19,20]. CPI-17 is involved in the 
phosphorylation of at least histone H3 Thr3, Ser10 and Thr11, offering a clue to find PP1 holoenzymes 
regulated by nuclear CPI-17.  Of particular interest, Repo-Man-PP1C is known to dephosphorylate 
histone H3 at Thr3, and a candidate of a CPI-17 target [24].  P-histone H3 Ser10 and Thr11 are also 
dephosphorylated by PP1, but the targeting subunit remains unknown [24]. Further systematic 
investigation is necessary for elucidating nuclear PP1 signaling regulated by CPI-17 in hyperplastic 
cancer and SM cells. 
The nuclear localization of CPI-17 in proliferating cells, but not in mature SM, was confirmed by 
fluorescent microscopy of endogenous proteins and ectopic 3xGFP-proteins. The N-terminal 21-residue 
tail, whose sequence is identical in mouse, pig and human, was mapped as the region required for 
nuclear localization.  This is consistent to our previous finding that FLAG-tagged CPI-17(1-120) and (1-
89) proteins are accumulated in nuclei of rat embryo fibroblasts [15]. We presume that the binding of 
importin complex to the N-terminal tail drives the nuclear import of CPI-17. This active nuclear import of 
CPI-17 is neutralized upon Ser12 phosphorylation, based on the data using the phospho-mimetic S12D 
protein and the phospho-specific antibody. Once CPI-17 is phosphorylated at Ser12, it is diffused but 
not excluded from nuclei, suggesting that nuclear export of CPI-17 is driven by diffusion, but not 
through active exporting mechanisms, such as CRM1 signaling. 3xGFP-CPI-17(∆N) and (S12D) was 
excluded from nuclei, because of the size (>78kDa).  It has known that PKC, ZIPK, ROCK and ILK, are 
capable of the phosphorylation of CPI-17 at Thr38 as well as Ser12 [7].  Our data here suggest that 
Ser12 phosphorylation occurs in cells.  In addition, there are two more Ser residues (Ser16 and Ser18) 
in the N-terminal tail of CPI-17, which may play an inhibitory role in the nuclear import. It is possible that 
pathological stresses alter the phosphorylation state at the N-terminal NLS of CPI-17 regulating the 
subcellular distribution of the signaling.  Identification of the kinases phosphorylating at Ser12 and 
adjacent sites will be a next step toward establishing pathological links between the redistribution of 
CPI-17 signaling and hyperplastic phenotype.  
In addition to CPI-17, other endogenous PP1 inhibitors are known to undergo nuclear shuttling, 
in response to environmental changes.  PP1 inhibitor-2 is redistributed from the nucleus to the 
cytoplasm, when the cell-cell contact is established [16].  Another soluble PP1 inhibitor, DARPP32, is 
actively imported into nuclei in response to amphetamine and cocaine treatments due to the 
phosphorylation at Ser97, resulting in the elevation in histone H3 Ser10 phosphorylation [25]. Nuclear 
shuttling of PP1 inhibitors may be a mechanism by which mammalian cells adjust phosphorylation 
levels in the nucleus in response to environmental changes. 
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FIGURE LEGEND 
 
Fig. 1:  Expression and localization of CPI-17 in Panc1 cells.  (A) QRTPCR for CPI-17 mRNA.  
Total RNA (200ng) of the cells indicated was subjected to QRTPCR analysis.  Extent of CPI-17 mRNA 
was normalized against lamin B, and the value of HEK293 was set as 1.0.  (B) Immunoblotting of CPI-
17 and actin using aorta tissue and cancer cell lysates. Total protein extracts (10µg) were subjected to 
immunoblotting.  The expression of CPI-17 in human pancreatic cancer cells (right panel) was 
visualized with longer exposure (“Longer exp.”), compared with left panel. HEK293; embryonic 
fibroblasts, HeLa; cervical adenocarcinoma, SH-SY5Y, neuroblastoma, SK-LMS1; leiomyosarcoma, 
and Panc1, L3.6pl, AsPC-1, BxPC-3; pancreatic cancers. (C) Immunofluorescence of Panc1 (top) and 
rat aorta SM cells (bottom) using anti-CPI-17 antibody.  Proliferating cells were fixed and stained with or 
without anti-CPI-17 antibody.  Control experiment was carried out without primary antibody (right).  
Scale bar, 10µm.  (D) Representing images of immunohistochemistry of rat aorta cross section with 
neointimal plaques.  At 14-days after balloon-catheter injury, rat aorta was subjected to fixation and 
sectioning.  Sections were co-stained with anti-CPI-17, anti-actin and Hoechst dye.  From top to 
bottom: lumen (indicated with ** in top left), neointima, SM layers.  Right panels show merged image of 
anti-CPI-17 staining with Hoechst staining. Bottom panels show the boxed area indicated in the panels 
above, respectively.  Arrows indicate cells showing prominent nuclear staining with anti-CPI-17. Scale 
bar, 10µm.  
 
Fig. 2:  Mechanisms underlying nuclear localization of CPI-17.  (A) Amino acid sequence of CPI-17 
at the N-terminal tail.  Arg, Lys and Ser are indicated in bold and underline respectively.  (B-L) 
Localization of 3xGFP proteins.  Rat aorta SM cells were transfected with the vectors encoding 3xGFP 
(B, G), 3xGFP-CPI-17(WT) (C, H), ∆N lacking the N-terminal 21 residues (D, I), S12A (E, J), and S12D 
(F, K), and visualized by immunofluorescence using anti-GFP. Bar indicates 10µm.  N/C Index was 
obtained from 8-10 cells.  *, p<0.05 compared to “Empty”. (M) CPI-17 phosphorylation at Ser12 in 
HEK293 cells.  HA-tagged CPI-17 was expressed in HEK293 cells for 24 h.  The transfected cells were 
harvested for 24 h without serum, followed by the stimulation for 10 min with 1 µM PMA, and subjected 
to immunoblotting using anti-P-S12-CPI-17.  Total CPI-17 was detected using anti-HA antibody. (N-T) 
Localization of phospho-CPI-17 at Ser12 in rat fundus SM cells.  TCA-fixed proliferating rat fundus SM 
cells were subjected to immunoblotting with anti-total CPI-17 (N) plus anti-P-S12-CPI-17 (O) or without 
primary antibodies (Q, R). Scale bar, 10µm. N/C index of P-S12-CPI-17 and total CPI-17 staining was 
obtained from 5 independent cells. *, p<0.05, compared to total CPI-17 staining.  
 
Fig. 3:  Binding of CPI-17 to nuclear PP1 in Panc1 cells. (A) Differential extraction and CPI-17 
pulldown assay.  Proliferating Panc1 cells were subjected to sequential extraction as described in 
Supplemental information (INPUT). Aliquot of the soluble fraction and the nuclear extracts were mixed 
with beads conjugated with unphosphorylated (U)-, tP-CPI-17 and no protein (BLK) and the bound 
proteins were analyzed by immunoblotting with antibodies indicated.  Sp1 was used as a marker of 
nuclear protein.  Anti-pan-PP1C antibody recognizes all isoforms.  (B) Specificity of CPI-17 binding to 
PP1 isoforms.  PP1 isoforms bound to tP-CPI-17-beads were determined using antibodies recognizing 
the isoforms.  Nuc. Ext.: input sample. 
 
 
Fig. 4.  Effects of CPI-17 knockdown on PP1 signaling in Panc1 cells. (A) Panc1 cells were 
transfected for 72 h with siRNA for CPI-17 (right lane) or non-targeting control (left lane, Ctl), and 
subjected to immunoblotting using antibodies against proteins indicated. P denotes phosphorylated 
protein. MLN; merlin, ERM; ezrin/radixin/moesin, H3; histone H3.  (B) Effects of CPI-17 knockdown on 
cell proliferation. After 72-h knockdown, cells were stained with hematoxylin, and the number of cells 
was counted under microscope.  The cell number before the knockdown was set as 1.0.  n=3, * p<0.05 
(Student’s t-test). 
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Supplemental information 
 
Material and Methods 
 
Cell culture:  The primary SM cells from rat aorta (AoSMC) and stomach fundus (SFSMC) were 
prepared using the enzymatic method, and harvested with 1:1 mixture of Dulbecco’s Modified Eagle 
Medium (DMEM) and Ham’s F12 supplemented with 10 % fetal bovine serum (FBS), as described 
previously [1].  Established cell lines of fibroblasts (HEK293 and COS1), cervical adenocarcinima 
(HeLa), neuroblastoma (SH-SY5Y), pancreatic carcinoma (Panc1), and leiomyosarcoma (SK-LMS-1) 
were purchased from ATCC. Immortalized cells were harvested with DMEM-10% FBS. Transfection of 
COS1 and SK-LMS-1 with the plasmid DNA and Panc1 with siRNA were performed using Xtremegene 
HP (Roche) and Lipofectamine RNAiMAX (Invitrogen), respectively.   
 
Others: Total RNA was prepared from the cells harvested in the growth medium in the presence of 
10 % FBS using Qiagen RNeasy total RNA preparation kit.  QRTPCR was performed in triplicate with 
200ng of total RNA and Brilliant II QRTPCR master mix kit with SyBr Green (Stratagene) using 
Mx3005P instrument.  The relative extent of mRNA was obtained by ∆∆Ct method using the value of 
lamin B mRNA and the extent in HEK293 sample as standards [1] [2]. The siRNA duplex targeting 
human CPI-17 mRNA 3’-noncoding region (GCUUGCUUGUGUAUAAGUUUU), siGENOME 
SMARTpool for CPI-17, and non-targeting control were obtained from ThermoScientific.  There was no 
significant difference in the results with two siRNA sets (data not shown). Subcellular fractionation was 
performed using Panc1 cells in 2x 10cm dishes.  First Panc1 cells were homogenized using a dounce 
homogenizer with 1 mL of the cytosolic extraction buffer consists of 10mM HEPES, 3mM MgCl2, 10% 
sucrose, 0.5mM TCEP, and 4mM Pefabloc™, pH7.2, and centrifuged for at 700 xg and 4 °C.  The 
supernatant was used as “the soluble fraction”.  The pellet was re-homogenized with 0.5mL of the 
nuclear extraction buffer including the cytosolic extraction buffer supplemented with 0.4M NaCl, 1% 
Triton X-100, 10% glycerol, and 20 U of DNase I.  After 15-min incubation on ice, the nuclear lysates 
were re-centrifuged for 16 min at 12,000rpm and 4°C, and the supernatant was used as “nuclear 
extracts” [3].  Each the soluble fraction and the nuclear extracts was split into three portions, and mixed 
at 4 °C with 15 µL of S-protein-agarose™ (Novagen) plus 1) none (BLK), and 20 µg of 2) 
unphosphorylated or 3) thiophosphorylated H6S-tagged CPI-17.  After 4-h incubation the beads were 
washed 3 times with 0.5 mL of the washing buffer (0.1 M NaCl, 50 mM MOPS-NaOH (pH 7.0), 1 mM 
EGTA, 0.1 % Tween 20, 5 % Glycerol, 0.5mM TCEP, and 4mM Pefabloc™), and the bound proteins 
were dissociated for 5 min at 100 °C with 50 µL of 2x Laemmli buffer.  The solution was subjected to 
immunoblotting and the bound proteins were visualized using Supersignal WestPico 
chemiluminescence reagent [4]. 
 
 
  
Supplemental table 1:  List of antibodies and a probe used in this work. 
 
Antibody Host Source 
Primary antibodies 
Anti-CPI-17 Rabbit Custom production by Cocalico Biol Inc, affinity purified [5] 
Anti-pan-actin Rabbit Sigma-Aldrich #A2066 
Anti-MYPT1 Mouse BD Biosciences #612164 
Anti-pan PP1C Chicken IgY Custom production and affinity purified at Aves Lab. Inc [6] 
Anti-PP1Ca Rabbit Custom production by QCB, affinity purified [6] 
Anti-PP1Cd Rabbit Custom production by QCB, affinity purified [6] 
Anti-PP1g1 Rabbit Calbiochem #539543 
Anti-2P-T18/S19 LC20 Rabbit Cell Signaling Tech. #3674 
Anti-P-S518-merlin Rabbit Abcam #ab115687 
Anti-P-T3-histone H3 Rabbit Cell Signaling Tech. #9714 
Anti-P-S10-histone H3 Rabbit Cell Signaling Tech. #9701 
Anti-retinoblastoma protein (Rb) Mouse Cell Signaling Tech. #9309 
Anti-sm-actin Mouse Sigma-Aldrich #A2547 
Anti-GFP Chicken IgY Aves Lab #GFP-1010 
Anti-P-T38-CPI-17 Chicken IgY Custom production and affinity purified at Aves Lab. Inc [7] 
Anti-P-S12-CPI-17* Chicken IgY Custom production and affinity purified at Aves Lab. Inc 
Anti-HA Mouse Purified IgG of 12CA5 clone [6] 
 
Secondary antibodies  
Anti-rabbit IgG-AF594 Goat Molecular Probes #A-11037 
Anti-chicken IgY-AF594 Goat Molecular Probes #A-11042 
Anti-rabbit IgG-OG488 Goat Molecular Probes #)-11038 
Anti-rabbit IgG-HRP Goat Jackson Immuno Lab #111-035-144 
Anti-chicken IgY-HRP Goat Jackson Immuno Lab #103-035-155 
Anti-mouse IgG-HRP Goat Jackson Immuno Lab #115-035-166 
 
 
* The chicken phospho-Ser12-specific CPI-17 IgY was prepared using a synthetic peptide 
(CZLGKRVLS(p)KLQSPSR) as antigen (Aves Labs).  The specific antibody was purified using the affinity resin 
conjugated with the phospho-peptide, followed by the absorption of non-specific fractions using the resin 
conjugated with recombinant CPI-17.   
 
 
  
Supplemental figure 1:  Fluorescence microscopy of 3xGFP protein expressed in COS1 
cells. 
 
 
 
  
Supplemental figure 2: Specificity of anti-P-S12-CPI-17. 
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